TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01227538

Intervention type: OTHER
Intervention: Mixed meal stimulated urinary C peptide for the assessment of residual beta cell function
Description: Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
Study: NCT01201070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antithrombin III
Description: 3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
Study: NCT02834052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:~Week 1, Days 1 and 4~Week 2, Days 8 and 11~Week 3, Days 15 and 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:~Week 1, Days 1 and 4~Week 2, Days 8 and 11~Week 3, Days 15 and 18
Study: NCT02194400

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RSLV-132
Description: 0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSLV-132
Description: 0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
Study: NCT01968096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: home-based ankle continuous passive motion machine.
Description: A rehabilitation program of machine driven passive stretch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: home-based ankle continuous passive motion machine.
Description: A rehabilitation program of machine driven passive stretch.
Study: NCT03696758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Testing
Description: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Testing
Description: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Subjects will undergo an electrocardiogram to ensure sinus rhythm
Study: NCT01965821

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous control of Pcuff followed by manual control
Description: continuous control of tracheal cuff pressure using an electronic device for 24 h followed by manual control of cuff pressure using a manometer

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual control of Pcuff followed by continuous control
Description: 24 h of manual control using a manometer followed by 24 h of continuous control using an electronic device
Study: NCT04064905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1893
Description: Zika vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study: NCT04337970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily~Phase II: MTD to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily~Phase II: MTD to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily~Phase II: MTD to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily~Phase II: MTD to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg PO BID
Study: NCT02921256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo intensity modulated radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo intensity modulated radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo intensity modulated radiation therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT03592329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tVNS
Description: non-painful electrical stimulation of the auricle
Study: NCT02921256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT03592329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tVNS
Description: non-painful electrical stimulation of the auricle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction Training B
Description: twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stress Reduction Training B
Description: twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions

Intervention type: DEVICE
Group type: OTHER
Intervention: sham tVNS
Description: sham stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: sham tVNS
Description: sham stimulation
Study: NCT03527654

Intervention type: OTHER
Intervention: Observational
Description: Surveys, blood and urine collected prospectively over 24 months.
Study: NCT01010035

Intervention type: OTHER
Intervention: Plasma kinetic study
Description: this study is done with the injection of LDL-like nanoemulsion doubly labeled with 14C- cholesteryl oleate and 3H- cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood sample collected in a pre established period of time in 24 hours.

Intervention type: OTHER
Intervention: Plasma kinetic study
Description: this study is done with the injection of LDL-like nanoemulsion doubly labeled with 14C- cholesteryl oleate and 3H- cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood sample collected in a pre established period of time in 24 hours.
Study: NCT02593344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endopat
Description: measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (Endopat)
Study: NCT02371993

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Choline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03485482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: bisoprolo 5 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine 10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of Ivabradine and bisoprolol
Description: combination of 10 mg ivabradine and 5 mg bisoprolol
Study: NCT02409940

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stem Cells
Description: These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.
Study: NCT01675076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: NOAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: NOAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: NOAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: NOAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: NOAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: NOAC
Study: NCT01281787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
Study: NCT01098110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg
Description: Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg
Description: Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg
Description: Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching placebo of asenapine sublingual tablet not containing asenapine
Study: NCT02344745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavandula angustifolia essential oil (Aura Cacia)
Description: The participants will be instructed to take a deep breath while holding the towel with two drops of essential oil 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: The participants will be instructed to take a deep breath while holding the towel with two drops of distilled water 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
Study: NCT04596124

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fitostimoline plus
Description: randomized controlled multicentric study

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fitostimoline plus
Description: randomized controlled multicentric study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fitostimoline plus
Description: randomized controlled multicentric study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fitostimoline plus
Description: randomized controlled multicentric study
Study: NCT04667936

Intervention type: OTHER
Intervention: Treatment group
Description: None, solely treatment documentation
Study: NCT02078921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06207292

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: The prescribed dose of stereotactic ablative radiotherapy (SABR) will be chosen based on the target to be treated and its proximity to organs at risk(s):~Lung-peripheral 33-45 Gy/ 3 fractions~Lung-central/ultra-central 35-60 Gy/5 fractions~Mediastinal/supraclavicular node 35-45 Gy/5 fractions~Liver 45-54 Gy/3 fractions; 50-65 Gy/5 fractions~Bone non-spine 30-36 Gy/3 fractions; 35-50 Gy/5 fractions~Bone spine 30-33 Gy/3 fractions (SIB); 35-40 Gy/ 5 fractions (SIB)~Abdominal-pelvic node 33-39 Gy/ 3 fractions; 35-50 Gy/5 fractions~Adrenal gland 30-42 Gy/3 fractions; 35-50 Gy/5 fractions
Study: NCT04467099

Intervention type: OTHER
Intervention: Foot Exam Follow-Up
Description: All participants will have a clinical assessment of their surgery foot by the study doctor.

Intervention type: OTHER
Intervention: Foot Exam Follow-Up
Description: All participants will have a clinical assessment of their surgery foot by the study doctor.

Intervention type: RADIATION
Intervention: X-ray
Description: Standard x-ray of the foot.

Intervention type: RADIATION
Intervention: X-ray
Description: Standard x-ray of the foot.

Intervention type: OTHER
Intervention: Questionnaire
Description: All participants will complete a questionnaire.

Intervention type: OTHER
Intervention: Questionnaire
Description: All participants will complete a questionnaire.
Study: NCT03490916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Administration of Acetazolamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of Placebo
Study: NCT02010255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily
Study: NCT00639431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: direct observation
Description: direct observation of another person's foot moving

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: direct observation
Description: direct observation of another person's foot moving

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: direct observation
Description: direct observation of another person's foot moving

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mental visualization
Description: mentally imagining moving one's phantom foot/feet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mental visualization
Description: mentally imagining moving one's phantom foot/feet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mental visualization
Description: mentally imagining moving one's phantom foot/feet
Study: NCT00972582

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine Increase
Description: Graded stepwise increases in leucine intakes (50, 250, 500, 750, 1000, 1250 and 1500mg/kg/day)
Study: NCT04676178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA023
Description: PRA023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA023
Description: PRA023

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02911857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab (AIN457)
Description: Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution
Study: NCT00545766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: Vinflunine 320 mg/m2 will be administered as a 20 minute IV infusion q3w. Patients will be evaluated for toxicity after each cycle of therapy. Response to vinflunine will be assessed every 6 weeks (every 2 cycles) of treatment. A maximum of 6 cycles of therapy are planned.
Study: NCT02021032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolieve
Description: Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
Study: NCT02004483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous coronary intervention is performed according to standard practice. Direct stenting is required for the procedure as it is done in most coronary interventions today. After insertion of the non-inflated stent into the coronary lesion there should still be flow to the distal vessel. The stent should be implanted at high-pressure with balloon inflation lasting for 60 seconds to allow adequate expansion of the stent. Post-dilatation should be performed if required. However, this should be done more than 5 minutes after stent implantation.
Study: NCT02114801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manual brushing
Description: Tooth brushing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electric toothbrush linked
Description: Tooth brushing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: off electric toothbrush
Description: Tooth brushing
Study: NCT03665454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562
Description: PF-06412562 is a dopamine agonist developed by Pfizer Inc. into a tablet form for oral usage. It will be provided as 5 mg tablets. Thus, to administer the 25 mg dose, 5 x 5 mg tablets will be given; and to administer the 20 mg dose, 4 x 5 mg tablets will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Placebo
Description: 25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
Study: NCT01524757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: pantoprazole 40mg 1dd1; 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pantoprazole
Description: pantoprazole 40mg 1dd1; 12 months
Study: NCT03375008

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Imaging diagnostic and biopsy
Description: Liver biopsy and MRI scan
Study: NCT01557049

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control Group
Description: No physical intervention was given, patients were treated only with medication if necessary.
Study: NCT02921256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT00013143

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient risk profiling (potential ADEs) w/provider feedback
Study: NCT02921256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT00103844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, oral, 20 mg and 50mg, twice daily, up to 96 weeks
Study: NCT01816113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 PvDBP 5 x 10^9
Description: 1 dose of ChAd63 PvDBP 5 x 10\^9 vp intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 PvDBP 5 x 10^10
Description: 1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly
Study: NCT00103844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Tablets, Oral, 400mg and 100mg, twice daily, up to 96 weeks
Study: NCT01852981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Strategies consisted of group discussion, some physical activities, phone support, and printed materials. The content and strategies were elaborated by a team formed by a doctor, nutritionists, a psychologist, and physical education professionals and the main aim was to promote the engagement in physical activity, working not only on behavioral change but also on the environment attributes available for physical activity practice. The main strategy was the group discussion, which sessions lasted 120 minutes each and its frequency changed as follow: in the first month they were weekly; in the second occurred twice per month; and in the third month onwards sessions were monthly. All sessions occurred in the Primary Health Unit or inside a community association building.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: Supervised exercise program in groups. Individuals in this program participated in three weekly structured and supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations. Load, intensity, and exercise adjustments were made during the program. All sessions lasted 60 minutes each and occurred in a gymnasium nearby the Primary Health Unit.
Study: NCT04026802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-Bed Resistance Training Device
Description: Physical Therapy using the in bed training device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Does not include early implementation of physical therapy
Study: NCT01816113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 PvDBP 5 x 10^10
Description: 1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 PvDBP 5 x 10^10
Description: 1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA PvDBP 1 x 10^8
Description: 1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA PvDBP 2 x 10^8
Description: 1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly
Study: NCT01802203

Intervention type: DEVICE
Intervention: truFreeze Spray Cryotherapy
Description: spray cryotherapy